Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood

Summary

By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were identified to accurately establish an early diagnosis model for liver cancer and verify its efficacy.

Eligibility

Inclusion Criteria:

1. Voluntarily sign informed consent.
2. Male or female, age equal to or greater than 18 years and less than 75 years.
3. Patients with liver cancer who have been diagnosed or suspected for the first time within 42 days prior to blood collection
4. The subject has not undergone any local or systemic anti-tumor therapy before blood collection, including (but not limited to) tumor surgical treatment for any purpose, local or systemic chemoradiotherapy, targeted therapy (including anti-angiogenic drugs), immunotherapy, cancer vaccine and hormone therapy, etc.
5. Patients with histologically or cytological, radiographically confirmed hepatocellular carcinoma.

Exclusion Criteria:

1. Female subjects who are pregnant or breastfeeding.
2. Previous organ transplantation or non-autologous bone marrow or stem cell transplantation.
3. Received drugs with anti-tumor effects for other diseases within 30 days before blood collection, such as drugs used for the treatment of immunorheumatic diseases such as methotrexate, cyclophosphamide, thiazoprine, chlorambucil, etc., drugs for the treatment of breast diseases, such as tamoxifen, etc.
4. History of previous malignant tumors.
5. Having other malignant tumors or multiple primary tumors at the same time.

Conditions4

Browse More Trials